Korean biotech company liable in gene therapy dispute
A Korean biotech company has been ordered to pay US$40 million in an ICC arbitration over the mislabelling of a gene therapy treatment, a matter that caused a scandal in Korea and led to the prosecution of executives.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.